Javascript must be enabled to continue!
Clinical features and outcome of influenza pneumonia in critically-ill immunocompromised patients
View through CrossRef
Immunocompromised subjects are at risk of severe viral infections which may require intensive care unit (ICU) admission. Data on the outcome of influenza pneumonia in critically-ill immunocompromised subjects are limited. We conducted a single-center observational study. All subjects admitted to the ICU for influenza pneumonia between 2016 and 2020 were included. The main objective was to compare the clinical features and outcome of critically-ill subjects with flu according to their immune status. 137 subjects (age 60 years-old, 58.4% male) were included, of whom 58 (42.34%) were intubated during the ICU stay. Forty-three (31.4%) subjects were immunocompromised. Immunocompromised subjects had a higher Charlson comorbidity index. In contrast, severity scores and hypoxemia at ICU admission, and ventilatory support during ICU stay were similar between the 2 groups. There was no difference in the rate of co-infections and ventilator-associated pneumonia between the 2 groups. Among intubated subjects, 10 (23.26%) immunocompromised subjects developed severe acute respiratory distress syndrome compared to 13 (13.83%) non-immunocompromised (P = .218). ICU mortality was 13.97%, with mortality being 3-times higher in immunocompromised subjects (25.58% vs 8.6%, P = .015). On multivariable analysis, immunocompromised status, higher age and lower arterial oxygen partial pressure/fraction of inspired oxygen were associated with an increased ICU mortality. Immunocompromised subjects with severe influenza pneumonia were more likely to develop severe acute respiratory distress syndrome and had a 3-fold increase in ICU mortality compared to non-immunocompromised subjects. Such difference was not explained by an increased rate of co-infections or nosocomial pneumonia, suggesting that influenza virus was by itself responsible of a more severe form of pulmonary disease in immunocompromised subjects.
Ovid Technologies (Wolters Kluwer Health)
Title: Clinical features and outcome of influenza pneumonia in critically-ill immunocompromised patients
Description:
Immunocompromised subjects are at risk of severe viral infections which may require intensive care unit (ICU) admission.
Data on the outcome of influenza pneumonia in critically-ill immunocompromised subjects are limited.
We conducted a single-center observational study.
All subjects admitted to the ICU for influenza pneumonia between 2016 and 2020 were included.
The main objective was to compare the clinical features and outcome of critically-ill subjects with flu according to their immune status.
137 subjects (age 60 years-old, 58.
4% male) were included, of whom 58 (42.
34%) were intubated during the ICU stay.
Forty-three (31.
4%) subjects were immunocompromised.
Immunocompromised subjects had a higher Charlson comorbidity index.
In contrast, severity scores and hypoxemia at ICU admission, and ventilatory support during ICU stay were similar between the 2 groups.
There was no difference in the rate of co-infections and ventilator-associated pneumonia between the 2 groups.
Among intubated subjects, 10 (23.
26%) immunocompromised subjects developed severe acute respiratory distress syndrome compared to 13 (13.
83%) non-immunocompromised (P = .
218).
ICU mortality was 13.
97%, with mortality being 3-times higher in immunocompromised subjects (25.
58% vs 8.
6%, P = .
015).
On multivariable analysis, immunocompromised status, higher age and lower arterial oxygen partial pressure/fraction of inspired oxygen were associated with an increased ICU mortality.
Immunocompromised subjects with severe influenza pneumonia were more likely to develop severe acute respiratory distress syndrome and had a 3-fold increase in ICU mortality compared to non-immunocompromised subjects.
Such difference was not explained by an increased rate of co-infections or nosocomial pneumonia, suggesting that influenza virus was by itself responsible of a more severe form of pulmonary disease in immunocompromised subjects.
Related Results
Correlation of Influenza Vaccination and Influenza Incidence on COVID-19 Severity and Other Perspectives
Correlation of Influenza Vaccination and Influenza Incidence on COVID-19 Severity and Other Perspectives
The pandemic of COVID-19 is evolving worldwide, and it is associated with high mortality and morbidity. There is a growing need to discuss the elements of a coordinated strategy to...
1395. Influenza B-Associated Pediatric Mortality in the US Between 2010 and 2019
1395. Influenza B-Associated Pediatric Mortality in the US Between 2010 and 2019
Abstract
Background
To assess the contribution of influenza B to mortality in the US pediatric population, we analyzed the propo...
A New Influenza-Tracking Smartphone App (Flu-Report) Based on a Self-Administered Questionnaire: Cross-Sectional Study (Preprint)
A New Influenza-Tracking Smartphone App (Flu-Report) Based on a Self-Administered Questionnaire: Cross-Sectional Study (Preprint)
BACKGROUND
Influenza infections can spread rapidly, and influenza outbreaks are a major public health concern worldwide. Early detection of signs of an infl...
Clinical characteristics and outcomes of patients with H1N1 influenza pneumonia admitted at a tertiary care hospital in Karachi, Pakistan
Clinical characteristics and outcomes of patients with H1N1 influenza pneumonia admitted at a tertiary care hospital in Karachi, Pakistan
Abstract
Introduction
Influenza viruses specifically, A and B mainly contribute to seasonal outbreaks that occur globally. However, due to limited diagnostics for influenza there i...
The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis
The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis
IMPORTANCE
COVID-19-infected pneumonia patients with severe immune abnormalities and risk of cytokine release syndrome. The definition, prevention, and treatment ...
U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic
U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic
Please cite this paper as: Borders‐Hemphill and Mosholder (2012) U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic. Influenza and...
Biomarkers in critically ill patients
Biomarkers in critically ill patients
We investigated whether biomarkers could (1) improve early diagnosis of sepsis (2) predict prognosis in patients with pneumonia and aneurysmal subarachnoid hemorrhage, (3) predict ...
The Clinical Effectiveness and Tolerability of Oseltamivir in Unvaccinated against Influenza Pediatric Patients in Two In-fluenza seasons after the COVID-19 pandemic.The Impact of Comorbidities on Hospitalization for Influenza in Children.
The Clinical Effectiveness and Tolerability of Oseltamivir in Unvaccinated against Influenza Pediatric Patients in Two In-fluenza seasons after the COVID-19 pandemic.The Impact of Comorbidities on Hospitalization for Influenza in Children.
Antiviral therapy such as Oseltamivir has been recommended for hospitalized children with suspected and confirmed influenza for almost 20 years. The therapy is officially authorize...

